Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Contact

Board of Directors/Management

The success of any company is through its management and leadership. MVP has a team of dedicated and experienced management specialists who seek new business opportunities and operate an efficient and profitable company. The company is overseen by its Board of Directors who offer an extensive knowledge base across business, finance and the health industry, who together, make the necessary decisions for the welfare of MVP’s shareholders and the growth of the company.

Management

Brent MacGregor
Chief Executive Officer

Anita James
Chief Financial Officer

Scott Courtney
Chief Scientific Officer

Neil Radford
Head of Operations

Jane Fisher
Head of Medical Affairs and Clinical Development

Chi Wai Ng
Head of Regulatory Affairs

Sindy Martino
Head of Commercial Operations for ANZ and International

Tony Wheal
Head of People & Culture

Board of Directors

Mr Gordon Naylor, BE (Hons), DipCompSc, MBA, CPA, GAICD, FTSE, MIE(Aust)
Non-Executive Chairman (since 18 December 2020)

Gordon has enjoyed a long and successful international business career.  For over 30 years he was a key part of the internationalisation of the CSL Group, a global specialty biotechnology company that was established in Australia and grew to become Australia’s largest public company.  Gordon held a range of business and functional leadership roles within CSL including Chief Financial Officer.  At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world.  In 2016 Seqirus was highly unprofitable with a turnover of circa $700m.  By 2019 the business generated circa $150m EBIT from a turnover of $1.2b.

Gordon holds a Bachelor of Engineering (Honours), a Graduate Diploma in Computer Science and an MBA as well as being a CPA and a graduate of the Australian Institute of Company Directors.

Mr Leon Hoare, AssocDipAppSc(Orth), GradDipBus, GAICD
Non-Executive Director (since 27 September 2013)

Mr Hoare is the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company.

Previously, he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015, one of Smith & Nephew’s largest global subsidiaries outside the USA. He served as President of Smith & Nephew’s Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in Marketing, Divisional and General Management.

His career has also included a senior role at Bristol-Myers Squibb (medical devices), and as Vice-Chair of the board of Australia’s peak medical device industry body, Medical Technology Association of Australia.

Mr Hoare is also the Chair of the Human Resources Committee.

Public company directorships in the past 3 years:
Polynovo Limited since 27 January 2016

Ms Christine Emmanuel-Donnelly, B.Sci (Hons), M. ENT, FIPTA, MAICD
Non-Executive Director (since 26 May 2020)

Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years’ experience locally and internationally. Ms Emmanuel-Donnelly is a former Executive Manager of Business Development and Commercial at the CSIRO, where she led the management of CSIRO’s IP team and IP portfolio for 14 years and managed the CSIRO equity portfolio for over 5 years. Prior to this role, Ms Emmanuel-Donnelly was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK), Davies Collison Cave and Griffith Hack in Melbourne.

Christine is also currently non-executive director of Polynovo Ltd, Pikcha Holdings Ltd, trading as Seminal, and on the Life Sciences Council of SBE Australia. She was previously Vice President of the Institute of Patent & Trademarks Attorneys of Australia for over 2 years, having been on the Board since 2010.

Public company directorships in the past 3 years:
Polynovo Limited since 13 May 2020

Ms M Sontrop, B.AppSci, Grad Dip Quality Mgt, Grad Dip Management (Health), MBA, FAICD
Non-Executive Director (since 5 March 2021)

Ms Sontrop has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration. During her 28 years with CSL Limited, Ms Sontrop was an integral part of CSL’s globalisation through a series of major acquisitions. This included primary responsibility for the turnaround of unprofitable manufacturing operations. Subsequently as head of global plasma manufacturing, Ms Sontrop delivered a globally integrated manufacturing network spanning four countries. As head of CSL’s Australia and New Zealand pharmaceutical business, Ms Sontrop and her team delivered Australia’s most successful adolescent/adult immunisation program and achieved USFDA (US Food & Drug Administration) approval to manufacture and export CSL’s seasonal and pandemic influenza vaccines. Ms Sontrop also has significant international governance experience.

Public company directorships in the past 3 years:
IDT Australia Limited from 1 March 2017 to 16 November 2021

Mr Richard Betts, B.Ec, ACA
Non-Executive Director (since 11 May 2021)

Mr Betts is an experienced executive who has held senior roles with ASX listed entities over 20 years.  Mr Betts is currently CFO at Ridley Corporation Limited and was previously CFO at Pact Group Holdings Ltd for 6 years.  Prior to that he held divisional finance and other executive roles at Orica Limited, these roles provided a deep understanding of working in various jurisdictions, including North America, Europe and Asia.  Mr Betts has extensive financial and governance experience within international manufacturing environments.

Dr Russell Basser (MBBS, MD, FRACP)
Non-Executive Director (since 31 August 2023)

Dr Basser is a qualified physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser’s worked as a medical oncologist in Melbourne prior to joining CSL in 2001.

During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has substantial expertise in international drug and vaccine development and spent several years based in the USA.

Dr Basser currently serves as a non-executive director on the Boards of Starpharma Holdings Limited and Doherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.

  • Investors/Media
  • Financial Reports
  • Board of Directors/Management
  • Media Centre
  • Corporate Governance
  • Diversity Policy
  • Share Trading Policy
  • Interviews/Analyst Reports

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY23 ASX Announcement

    31 August 2023 ASX Announ...

  • Medical Developments International Ltd awarded up to $1.5M in funding for next generation Penthrox® device

    Media Announcment Medical...

  • FY23 Half Year ASX Announcement

    24 February 2023 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter